Key result
Levosimendan reversibly binds cysteine 84 to stabilize active calcium-bound cTnC.
This study elucidates the molecular mechanism of levosimendan, demonstrating it sensitizes cardiac muscle by forming a reversible covalent bond with cysteine 84 of the Ca2+-bound conformation of cardiac troponin C.
No immediate change to levosimendan use; leaves open translation of this troponin C mechanism to human therapies.
The binding of Ca2+ to cardiac troponin C (cTnC) triggers contraction in heart muscle. In the diseased heart, the myocardium is often desensitized to Ca2+, which leads to impaired contractility. Therefore, compounds that sensitize cardiac muscle to Ca2+ (Ca2+-sensitizers) have therapeutic promise. The only Ca2+-sensitizer used regularly in clinical settings is levosimendan. While the primary target of levosimendan is thought to be cTnC, the molecular details of this interaction are not well understood. In this study, we used mass spectrometry, computational chemistry, and nuclear magnetic resonance spectroscopy to demonstrate that levosimendan reacts specifically with cysteine 84 of cTnC to form a reversible thioimidate bond. We also showed that levosimendan only reacts with the active, Ca2+-bound conformation of cTnC. Finally, we propose a structural model of levosimendan bound to cTnC, which suggests that the Ca2+-sensitizing function of levosimendan is due to stabilization of the Ca2+-bound conformation of cTnC.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (2016) studied Impaired cardiac contractility. Levosimendan was evaluated on Molecular binding mechanism to cardiac troponin C (cTnC). Levosimendan reacts specifically with cysteine 84 of the active, Ca2+-bound conformation of cardiac troponin C to form a reversible thioimidate bond, stabilizing the Ca2+-bound conformation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: